Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2014 | Pages:
57 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Swedish Orphan Biovitrum AB - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Swedish Orphan Biovitrum AB - Product Pipeline Review - 2014', provides an overview of the Swedish Orphan Biovitrum AB's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Swedish Orphan Biovitrum AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Swedish Orphan Biovitrum AB including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Swedish Orphan Biovitrum AB's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Swedish Orphan Biovitrum AB's pipeline products Reasons to buy - Evaluate Swedish Orphan Biovitrum AB's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Swedish Orphan Biovitrum AB in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Swedish Orphan Biovitrum AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Swedish Orphan Biovitrum AB and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Swedish Orphan Biovitrum AB - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Swedish Orphan Biovitrum AB and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Swedish Orphan Biovitrum AB Snapshot 5 Swedish Orphan Biovitrum AB Overview 5 Key Information 5 Key Facts 5 Swedish Orphan Biovitrum AB - Research and Development Overview 6 Key Therapeutic Areas 6 Swedish Orphan Biovitrum AB - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Swedish Orphan Biovitrum AB - Pipeline Products Glance 15 Swedish Orphan Biovitrum AB - Late Stage Pipeline Products 15 Pre-Registration Products/Combination Treatment Modalities 15 Phase III Products/Combination Treatment Modalities 16 Swedish Orphan Biovitrum AB - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 Swedish Orphan Biovitrum AB - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Swedish Orphan Biovitrum AB - Unknown Stage Pipeline Products 20 Unknown Products/Combination Treatment Modalities 20 Swedish Orphan Biovitrum AB - Drug Profiles 21 anakinra 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 nitisinone 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 bucelipase alfa 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 collagenase clostridium histolyticum 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 palifermin 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 SOBI-003 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Swedish Orphan Biovitrum AB - Pipeline Analysis 34 Swedish Orphan Biovitrum AB - Pipeline Products by Target 34 Swedish Orphan Biovitrum AB - Pipeline Products by Route of Administration 35 Swedish Orphan Biovitrum AB - Pipeline Products by Molecule Type 36 Swedish Orphan Biovitrum AB - Pipeline Products by Mechanism of Action 37 Swedish Orphan Biovitrum AB - Recent Pipeline Updates 38 Swedish Orphan Biovitrum AB - Dormant Projects 49 Swedish Orphan Biovitrum AB - Discontinued Pipeline Products 50 Discontinued Pipeline Product Profiles 50 bumetanide 50 nitisinone 50 Swedish Orphan Biovitrum AB - Company Statement 51 Swedish Orphan Biovitrum AB - Locations And Subsidiaries 54 Head Office 54 Other Locations & Subsidiaries 54 Appendix 56 Methodology 56 Coverage 56 Secondary Research 56 Primary Research 56 Expert Panel Validation 56 Contact Us 57 Disclaimer 57
List of Tables Swedish Orphan Biovitrum AB, Key Information 5 Swedish Orphan Biovitrum AB, Key Facts 5 Swedish Orphan Biovitrum AB - Pipeline by Indication, 2014 8 Swedish Orphan Biovitrum AB - Pipeline by Stage of Development, 2014 9 Swedish Orphan Biovitrum AB - Monotherapy Products in Pipeline, 2014 10 Swedish Orphan Biovitrum AB - Partnered Products in Pipeline, 2014 11 Swedish Orphan Biovitrum AB - Partnered Products/ Combination Treatment Modalities, 2014 12 Swedish Orphan Biovitrum AB - Out-Licensed Products in Pipeline, 2014 13 Swedish Orphan Biovitrum AB - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 Swedish Orphan Biovitrum AB - Pre-Registration, 2014 15 Swedish Orphan Biovitrum AB - Phase III, 2014 16 Swedish Orphan Biovitrum AB - Phase II, 2014 17 Swedish Orphan Biovitrum AB - Phase I, 2014 18 Swedish Orphan Biovitrum AB - Preclinical, 2014 19 Swedish Orphan Biovitrum AB - Unknown, 2014 20 Swedish Orphan Biovitrum AB - Pipeline by Target, 2014 34 Swedish Orphan Biovitrum AB - Pipeline by Route of Administration, 2014 35 Swedish Orphan Biovitrum AB - Pipeline by Molecule Type, 2014 36 Swedish Orphan Biovitrum AB - Pipeline Products by Mechanism of Action, 2014 37 Swedish Orphan Biovitrum AB - Recent Pipeline Updates, 2014 38 Swedish Orphan Biovitrum AB - Dormant Developmental Projects,2014 49 Swedish Orphan Biovitrum AB - Discontinued Pipeline Products, 2014 50 Swedish Orphan Biovitrum AB, Other Locations 54 Swedish Orphan Biovitrum AB, Subsidiaries 54
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
